  
 
Clinical Protocol REN- 003 
 
A Phase 1b dose -escalating study with Stannous  Protoporphyrin 
(SnPP) , in healthy volunteers and subjects with chronic kidney 
disease stage 3 -4 
  
IND 138109  
 
SPONSOR 
Renibus Therapeutics, Inc.  
950 E State Highway 114, Suite 160 
Southlake, TX 76092 
   
Original Protocol:  25 March  2019 
      
 
 
 
CONFIDENTIALITY STATEMENT  
Part or all of the information in this protocol may be unpublished material . Accordingly, 
this protocol is to be treated as confidential and restricted to its intended use. This 
material is the property of Renibus Therapeutics, Inc.  and must not be disclosed or used 
except as authorized in writing by Renibus Therapeutics,  Inc..
Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 2 of 38 
Table of Contents 
1 STUDY TITLE  ............................................................................................................ 4 
2 SPONSOR INFORMATION  ...................................................................................... 4 
2.1 Sponsor: ............................................................................................................... 4 
2.2 Sponsor Representative:....................................................................................... 4 
3 LIST OF ABBREVIATIONS  ..................................................................................... 5 
4 STUDY SYNOPSIS  .................................................................................................... 7 
5 EVENT SCHEDULE  ................................................................................................ 14 
5.1 Event Schedule – All subjects ............................................................................ 14 
6 INTRODUCTION  ..................................................................................................... 15 
6.1 Background Information .................................................................................... 15 
6.2 Study Drug  ......................................................................................................... 16 
6.3 Preclinical Experience  ....................................................................................... 16 
6.4 Clinical Experience ............................................................................................ 16 
7 STUDY OBJECTIVES  ............................................................................................. 16 
7.1 Primary Objectives ............................................................................................. 16 
8 INFORMED CONSENT  ........................................................................................... 17 
9 STUDY POPULATION  ............................................................................................ 17 
9.1 Healthy Volunteer (HV)  .................................................................................... 17 
9.1.1 HV Inclusion Criteria  ................................................................................ 17 
9.1.2 HV Exclusion Criteria ............................................................................... 18 
9.2 CKD Subjects ..................................................................................................... 18 
9.2.1 CKD Inclusion Criteria  ............................................................................. 18 
9.2.2 CKD Exclusion Criteria  ............................................................................ 19 
9.3 Study Design  ...................................................................................................... 19 
9.3.1 Stopping Rules .......................................................................................... 20 
9.4 Recordkeeping and Monitoring ......................................................................... 20 
9.5 Investigational Supplies ..................................................................................... 21 
9.5.1 Study Drug Description  ............................................................................ 21 
9.5.2 Packaging  .................................................................................................. 21 
9.5.3 Investigational Product Dispensi
ng .......................................................... 21 
9.5.4 Dosage Preparation and Administration ................................................... 21 
9.5.5 Storage Requirements  ............................................................................... 22 
9.5.6 Investigational Product Accountability ..................................................... 22 
9.5.7 Retrieval and Destruction  ......................................................................... 22 
9.6 Study Visits  ........................................................................................................ 22 
9.6.1 General Information  .................................................................................. 22 
9.6.2 Screening (Within 14 Days Prior to Study Day 1) ................................... 22 
9.6.3 Study Day 1 ............................................................................................... 23 
9.6.4 Study Day 2 ............................................................................................... 24 
9.6.5 Study Days 3,4,5,8 (Day 8 ±  1 day) .......................................................... 24 
9.6.6 Study Day 14............................................................................................. 25 
9.6.7 Study Day 29/End of Study Visit (28 ±  1 days following the SnPP dose) 25 
9.7 Clinical Laboratory Evaluations ........................................................................ 25 Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 3 of 38 
9.7.1 Blood Chemistry, Hematology, Pharmacokinetic and Response biomarker Samples  ..................................................................................................... 25 
9.7.2 Urine Samples  ........................................................................................... 25 
9.8 Clinical Procedures and Observations ............................................................... 26 
9.8.1 ECG ........................................................................................................... 26 
9.8.2 Concomitant Medications ......................................................................... 26 
9.8.3 Physical Examination ................................................................................ 26 
9.8.4 Vital Signs  ................................................................................................. 26 
9.8.5 Meals and Dose Administration ................................................................ 26 
9.8.6 Prohibited Medications ............................................................................. 26 
10 ADVERSE EVENT REPORTING  ........................................................................... 26 
10.1 Investigator Reporting Requirements ................................................................ 26 
10.2 Definitions .......................................................................................................... 27 
10.3 Breaking the Blind  ............................................................................................. 29 
11 STATISTICAL CONSIDERATIONS  ...................................................................... 29 
11.1 Study Populations .............................................................................................. 29 
11.2 Demographic and Baseline Characteristics  ....................................................... 29 
11.3 Analysis of Efficacy Endpoints ......................................................................... 30 
11.4 Analysis of Pharmacodynamic/Safety Endpoints .............................................. 30 
11.5 Analysis of Pharmacokinetic (PK) Data  ............................................................ 30 
11.6 Sample Size Calculations  ................................................................................... 31 
11.7 Interim Analysis  ................................................................................................. 31 
12 WITHDRAWAL FROM STUDY ............................................................................ 31 
13 DATA MANAGEMENT  .......................................................................................... 32 
13.1 Database Lock  .................................................................................................... 32 
14 ETHICAL CONSIDERATIONS  .............................................................................. 32 
14.1 Ethical Conduct of the Study ............................................................................. 32 
14.2 Regulatory Considerations ................................................................................. 33 
14.3 Protocol Amendments and Study Termination .................................................. 33 
14.4 Safety Monitoring .............................................................................................. 33 
14.5 Quali
ty Control and Quality Assurance ............................................................. 33 
15 GENERAL CONSIDERATIONS  ............................................................................. 34 
15.1 Discontinuation of the Study ............................................................................. 34 
16 AGREEMENT WITH PROTOCOL  ......................................................................... 35 
17 REFERENCES  .......................................................................................................... 36 
  
Appendices  
 
Appendix 1  Safety Clinical Chemistry, Hematology, and Urinalysis Tests Performed by the Laboratory at Screening, During the Study, and at Follow-up (EOS)……38  
     Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 4 of 38 
1 STUDY TI TLE 
A Phase 1b dose- escalating study with Stann ous Protoporphyrin ( SnPP), in healthy volunteers 
and subject s with chronic kidney disease stage 3-4 
2 SPONSOR INFORMATION 
2.1 Sponsor:  
Name:  Renibus Therapeutics, Inc.  
Address:  950 E State Highway 114, Suite 160  
 Southlake, TX 76092  
2.2 Sponsor Representative:  
Name:  Bhupinder Singh , MD, FASN, FNKF , FCRS  
 
Title  Chief Scientific Officer and Medical  Monitor  
Affiliation:  Renibus Therapeutics, Inc.  
Address:  950 E State Highway 114, Suite 160  
Southlake, TX 76092  
Mobile:  (480) 220 -7084  
E-mail:  medicalmonitor@renibus.com  
 ______________________________  _____________________ Bhupinder Singh, MD, FASN, FNKF , FCRS     Date  
Chief Scientific Officer and Medical  Monitor 
Renibus Therapeutics, Inc.  
  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 5 of 38 
3 LIST OF ABBREVIATIONS  
 
Abbreviation  Definition  
AE  Adverse event   
AKI acute kidney injury  
ALT  alanine aminotransferase  
ARB  angiotensin -receptor blockers  
AST  aspartate aminotransferase  
AUC (0-t) area under the concentration -time curve from time  0 to t  
AUC (0-inf) area under the concentration -time curve from time 0 to infinity  
BUN  blood urea nitrogen  
CFR  Code of Federal Regulations  
CIOMS  Council for International Organizations of Medical Sciences  
CKD  chronic kidney disease  
CL clearance  
Cmax maximum serum  or plasma  concentration  
Cr creatinine  
CRO  contract research organization  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
FDA  Food and Drug Administration  
FeS Iron sucrose  
GCP  Good Clinical Practice  
GFR  glomerular filtration rate  
GLP  Good Laboratory Practice  
HO-1 Heme oxygenase  
ICF informed consent form  
ICH International Conference on Harmonisation  
ICSR  Individual Case Safety Report  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IV intravenous  
Ll-6 Interleukin 6  
IL-10 Interleukin 10  
IND investigational new drug  
IRB Institutional Review Board  
ITT Intent -to-Treat  
KDIGO  
KIM -1 Kidney Disease: Improving Global Outcomes  
Kidney Injury Molecule -1 Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 6 of 38 
Abbreviation  Definition  
λz elimination rate constant  
MedDRA  Medical Dictionary for Regulatory Activities  
MITT  
NAG  
NGAL  Modified Intent -to-Treat    
N acetyl -beta-D-glucosaminidase  
Neutrophil Gelatinase -Associated Lipocalin  
NOAEL  no-observed -adverse -effect level  
PK Pharmacokinetic(s)  
POC  Proof of Concept  
PP Per Protocol  
SnPP  Stannous Protoporphyrin  
TEAE  treatment emergent adverse event  
T½ elimination half -life  
Tmax  time to maximum serum concentration  
Vz volume of distribution  
    Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 7 of 38 
4 STUDY SYNOPSIS  
Renibus Therapeutics, Inc.  Protocol N o. REN -003 
Name of Drug: Stannous  Protoporphyrin (SnPP)  Phase of Development: 1b 
Name of Active Ingredient:  
Stannous protoporphyrin  (SnPP)  Date of Study Synopsis  
25 March  2019 
Protocol Title:  
A Phase 1b dose- escalating study with Stannous Protoporphyrin ( SnPP ), in healthy volunteers 
and subjects with chronic kidney disease stage 3 -4. 
Investigational S ites: 
One contract research organization in the US . 
Study Objectives:  
The primary objectives of the study are to evaluate:  
1. The safety and tolerability of SnPP in healthy volunteers and in subjects with stage 3 -4 
chronic kidney disease ( CKD). 
2. The effect of SnPP on biomarkers which are potential surrogates for cytoprotective activity in healthy volunteers and in subjects with stage 3 -4 (CKD).  
3. To establish the optimal dose that could potentially be used in combination with iron 
sucrose for testing in subject s at risk for developing acute kidney injury ( AKI). 
4. To study the Pharmacokinetics of SnPP 
Number  Subjects to be Enrolled:  
Up to a total of 42 subjects consisting of 18 healthy volunteers and 24 subjects with chronic 
kidney disease will receive single escalating doses of SnPP . 42 subjects consisting of 18 healthy 
and 24 subjects with stage 3 -4 CKD will be enrolled in one of three  dose levels starting at the 
lowest dose of 9 mg  SnPP for the Healthy volunteers and starting at the lowest dose of 27 mg 
SnPP for 3 -4 CKD patients. 
Study Design:  
This is a Phase 1b, single-center, dose- escalating study to evaluate the safety, tolerability, PK and 
pharmacodynamic effect of  SnPP in healthy volunteers and in subjects with stage 3 -4 CKD. The 
following biomarkers will be used as surrogate measures of cyto protective activity: Haptoglobin, 
Ferritin, Bilirubin, Hemopexin, IL-10, and H eme O xygenase-1.  Additionally, the P21 biomarker 
will be monitored at various points of the study  as well as urine biomarker response to SnPP .  
Screening data will be reviewed to determine subject eligibility. Subjects  who meet all inclusion 
criteria and none of the exclusion criteria are eligible to be enrolled into the study.   The study is designed as follows:  
• A screening period with baseline evaluations for study eligibility.  
• Baseline for various  biomarkers will be established by three different measuremen ts in 
blood and urine prior to dosing. 
• If subjects meet eligibility criteria, they will receive a single dose of SnPP by slow intravenous injection over a 120-minutes on study day (SD) 1.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 8 of 38 
• Subjects will stay in the clinic for the initial 24 hours after administration of  SnPP  and 
will be discharged at the end of SD  2 if no safety issues appear.  
• The study will initially be dose- escalating in 3 groups of 6 healthy volunteers each, for a 
total of 18 healthy volunteers , evaluating escalating single dose of Sn PP starting with a 
dose of 9 mg SnPP, followed by 27 mg  SnPP, and 90 mg SnPP.  Dose -escalation from 
one dose level to the next will only be allowed after a careful review of the safety , 
tolerability and PK data from the prior dose group as determined by the D ata and  Safety 
Monitoring Board (DSMB) . 
• After a careful review of the safety , tolerability and PK data from all  dose groups from 
the healthy volunteer cohorts, the D ata and  Safety Monitoring Board (DSMB) will 
determine whether to proceed to the CKD cohorts. If the determination by the DSMB allows to proceed to the CKD cohorts, subjects with stage 3 CKD will be in 2 groups of 6 each, for a total of 12 subjects, evaluating escalating single dose of SnPP starting with a dose of 27 mg SnPP followed by 90 mg SnPP.  Dose -escalation from one dose level to 
the next will only be allowed after a careful review of the safety , tolerability and PK data 
from the prior dose group as determined by the D ata and  Safety Monitoring Board 
(DSMB) . 
• After a c areful review of the safety , tolerability and PK data from all  dose groups from 
the stage 3 CKD cohorts, the D ata and  Safety Monitoring Board (DSMB) will determine 
whether to proceed to the stage 4 CKD cohorts. If the determination by the DSMB allows to proceed to the stage 4 CKD cohorts, subjects with stage 4 CKD will be in 2 groups of 
6 each, for a total of 12 subjects, evaluating escalating single dose of SnPP starting with a 
dose of 27 mg SnPP followed by 90 mg SnPP.  Dose -escalation from one dose level to 
the next will only be allowed after a careful review of the safety , tolerability and PK data 
from the prior dose group as determined by the D ata and  Safety Monitoring Board 
(DSMB) . 
• Subjects will be followed for 28 days after the dose of  SnPP. Response b iomarkers will 
be assessed at baseline and 2, 4, 8, 12, 18, 24, 48, 72, 96 and 168 hours after study drug 
administration. Safety will be assessed for up to 28 days after study drug administration.  
• Blood samples for SnPP pharmacokinetic analysis will be a ssessed at baseline and 1, 2, 3, 
4, 6, 8, 12, 18, and 24 hours after study drug administration. These data will be used in 
the dose escalation decision making review process along with the safety and tolerability of the previous dose.  Urine samples will be collected and centrifuged and analyzed for 
subject responsiveness to SnPP therapy.
 
• Urinary Clearance of SnPP will be assessed by the measurement of tin in a 24 -hour urine 
sample 
• Total study duration wi ll be 29 days for each  subject , in addition to a screening period of 
up to 14 days.  
Endpoints:  
Pharmacodynamic/ Safety Assessment : Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 9 of 38 
The safety and tolerability of  SnPP will be assessed by determining the incidence, relationship to 
study drug, and severity of treatment -emergent adverse events ( TEAEs ), withdrawals due to 
adverse events ( AEs), and changes in vital signs, laboratory tests, changes in concomitant 
medication use due to AEs, and other standard safety parameters. In addition, Blood Urea Nitrogen ( BUN), creatinine , Cystatin -C, Kidney Injury M olecule- 1 (KIM -1), 
Neutrophil 
Gelatinase- Associated Lipocalin (NGAL),  albuminuria, N acetyl -beta-D- glucosaminidase 
(NAG),  liver enzymes, and troponin I. 
Biomarker Monitoring 
The following biomarkers will be evaluated:  Haptoglobin (Hp) , Ferritin and bilirubin, 
Hemopexin, IL-10, H eme Oxygenase 1 (HO -1) and P21, as well as urine biomarker response to 
SnPP. B iomarkers will be measured at baseline and 2, 4, 8, 12, 18, 24, 48, 72, 96 and 168 hours 
after administration of SnPP . All biomarkers  will be measured at the same time points.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 10 of 38 
Healthy Volunteer Subjects  
 Inclusion Criteria:  
1. Male and female subject s age 18 to 80 years (inclusive, at time of ICF). 
2. Body weight <125 kg. 
3. Able and willing to comply with all study procedures. 
4. Female subjects must be either post -menopausal for at least 1 year or surgically sterile 
(tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or  abstain from sexual activity from Screening until 28 days after study 
drug administration.  
Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 28 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation. 
Exclusion Criteria:  
1. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non- melanoma skin cancers. Cancer free for less than five years.  
2. Use of investigational drugs or participation in another clinical trial within 30 days or <5 half- lives prior to screening, whichever is longer . 
3. Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screening. 
4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study. 
5. Any significant acute or chronic diseases.    
6. 
Subjects with abnormal baseline liver tests  or hepatitis serologies that suggest 
active infection.  
7. Regular use of drugs of abuse and/or positive findings on urinary drug screening.  
8. Current tobacco use and/or positive findings on urinary cotinine screening.  
9. Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects’ tasks associated with the protocol . 
10. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated . 
11. Subjects with history of photosensitivity or active skin disease , which in the opinion of 
the investigator could increase the risk of photosensitivity.  
12. Known hypersensitivity or previous anaphylaxis to SnPP  or tin based product. Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 11 of 38 
CKD Subjects  
 Inclusion Criteria:  
1. Male and female subject s age 18 to 80 years (inclusive, at time of ICF). 
2. Body weight <125 kg. 
3. Able and willing to comply with all study procedures. 
4. Female subjects must be either post -menopausal for at least 1 year or surgically sterile 
(tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or  abstain from sexual activity from Screening until 28 days after study 
drug administration.  
Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 28 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation. 
5. CKD stage 3 as determined by a GFR between 30-59 ml/min as estimated using the CKD -EPI equation. 
6. CKD stage 4 as determined by a GFR between 15-29 ml/min as estimated using the CKD -EPI equation. 
Exclusion Criteria:  
1. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non- melanoma skin cancers.  Cancer free for less than 5 years.  
2. Use of investigational drugs or participation in another clinical trial within 30 days or 5 half- lives prior to  screening, whichever is longer . 
3. Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screening, or currently being treated with oral iron. 
4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in th e study. 
5. Regular use of drugs of abuse and/or positive findings on urinary drug screening.  
6. Current tobacco use and/or positive findings on urinary cotinine screening.  
7. Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects’ tasks associated with the protocol . 
8. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated. 
9. Subjects with history of photosensitivity or active skin disease , which, in the opinion of 
the investigator could increase the risk of photosensitivity.  
10. Subjects with abnormal baseline liver tests or hepatitis serologies that suggest active infection. 
11. Subjects with CKD and not at their baseline of renal function and have significant acute 
or chronic illnesses.  
12. Known hypersensitivity or previous anaphylaxis to SnPP  or to components thereof. Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 12 of 38 
Drug, Dose and Mode of Administration:  
SnPP is supplied as  a sterile liquid in vials for intravenous (IV) injection and intended for single 
use. Glass vials are plugged with Teflon -coated rubber stoppers and sealed with aluminum seals. 
Vials of  5 mL will be used  for each cohort . 
SnPP at a dose of either 9 mg SnPP, 27 mg SnPP,  or 90 mg SnPP will be administered on SD  1. 
The infusions will  be given using a syringe pump over a 120-minute period.  
Rationale for the Dose and Schedule Selection:  
The proposed SnPP doses and administration schedules are based on previous human studies with SnPP and preclinical pharmacology and toxicology data. The proposed starting dose of 9 mg SnPP is 1/ 10 the NOA EL in rats and 1/36 th e NOAEL in dogs 
based on body surface scaling 
in accordance with the conversion factors in Appendix A of the Guidance for Industry 
Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in 
Adult Healthy Volunteers (2005)  and a human body weight of 60 kg, and has previously 
been administered safely to human subjects.  
Study Duration:  
Study duration is for 29 days per subject . 
Criteria for Evaluation:  
Biomarkers 
• Key parameters: Haptoglobin, F erritin , Hemopexin, IL-10, H eme O xygenase 1 (HO -1) 
and B ilirubin . Urine samples will be collected and centrifuged and analyzed for subject 
responsiveness to SnPP therapy. 
• Additional secondary parameters: P21   
Pharmacodynamic/ Safety parameters  
• Blood Urea Nitrogen (BUN), creatinine, Cystatin -C, Kidney Injury Molecule-1 ( KIM -1), 
Neutrophil Gelatinase-Associated Lipocalin (NGAL), albuminuria, N acetyl -beta-D-
glucosaminidase (NAG),  liver enzymes and troponin I at regular intervals  
• Adverse events, serious adverse events, suspected adverse reactions, and serious unexpected suspected adverse reactions  
• Laboratory safety data, vital signs, and temperature at regular intervals  
Pharmacokinetics  
• SnPP on SD 1  
Study Hypothesis:  
It is hypothesized that SnPP  is safe and well tolerated up to the top dose of 90 mg SnPP. It is also 
hypothesized that SnPP  will modulate  biomarker levels in a dose -related fashion.  
Statistical Considerations  
Sample Size : No formal sample size calculation has been performed for this phase 1b study. 
However, it is believed that six  subject s per dose group in the healthy volunteer cohorts (3) and 
the CKD  stages 3 & 4  cohorts (2  each ) will be adequate to establish POC based on biomarker 
response and identify an optimal dose for further testing, recognizing that a battery of different surrogate biomarkers will be evaluated  
Analysis Populations and General Methodology:  All subjects who receive study medication 
will be included in the Safety population for safety analysis. Subject s who receive study 
medication and have a post -baseline efficacy assessment will be included in the Modified Intent-Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 13 of 38 
to-Treat (MITT) population for efficacy analysis. All subject  data will be listed. When  
appropriate, summary statistics will be provided (number of non- missing values, mean, median, 
standard deviation, minimum, and maximum for continuous variables and number and percentage of subjects for categorical variables) by treatment group for all measures, including demographic and baseline assessments, safety, and efficacy endpoints. Baseline for all safety and efficacy endpoints is defined as the last observations before administration of the first IV infusion of study drug. No imputation will be used for missing data. 
Safety Analysis:  Safety measures including AEs, infusion- related reactions, clinical laboratory 
tests, vital signs, physical exams, and concomitant medication usage will be summarized descriptively by treatment group and study visit, where appropriate.  Biomarker Analysis:  Biomarker response will be summarized by treatment group and study 
visit, comparing change from baseline at  2, 4, 8, 12, 18, 24, 48, 72, 96 and 168 hours after start of 
infusion . 
Percent change from baseline will be analyzed using the mixed model for repeated measures (MMRM). The between -group comparison will be performed using the simple contrast at 2, 4, 8, 
12, 18, 24, 48, 72, 96 and 168 hours post-dosing In addition to absolute and percent changes from baseline, a r esponder analysis will also be 
considered. The responder definition and its appropriate analysis methodology will be detailed in the statistical analysis plan (SAP) for the study. Exploratory analysis using Cochran -Mantel -
Haenszel test stratified by baseline or primary diagnosis will be carried out. 
Pharmacokinetic Analysis: Pharmacokinetic parameters of each treatment group will  be 
estimated using a non-compartmental analy sis following completion of each dose and prior to 
dose escalation .  The maximum serum concentration (C max) and time to maximum serum 
concentration (Tmax) will be obtained directly from the data. The elimination rate constant (λz), 
elimination half -life (T ½), area under the concentration -time curve from time 0 to time t (AUC [0-t]) 
and area under the concentration -time curve from time 0 to infinity (AUC [0-inf]), clearance (CL), 
and volume of distribution (Vz) will be calculated for each subject and summarized by treatment 
group. The renal excretion and renal clearance (CL) of tin will al so be calculated.  
A compartmental model may be fit to the data if appropriate and used to predict plasma 
concentration -time profiles for other doses and regimens 
 
  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 14 of 38 
5 EVENT SCHEDUL E 
5.1 Event Schedule – All subject s 
Study Day  Screening  
 1 2,3,4,5,81 14** 29/End  of Study1 
Parameter  Within 14 days prior to first dose      
Written informed consent X     
Eligibility criteria  X     
Demographics  X     
Medical history  X     
Physical examination and weight  X X2   X 
Electrocardiogram  X X2,3   X 
Vital signs  X X2 X  X 
Serum chemistry8,9 X X2 X  X 
Hematology8,9 X X2 X  X 
Baseline determination13 X X    
Response  biomarkers8,11  X2,4 X   
Safety biomarkers8,12  X2 X X X 
SnPP PK4,11  X    
Urinalysis including sediment9 X X2 X  X 
Urine pregnancy test10 X            X X at Day 8   X 
Urine drug/alcohol/cotinine screen X     
Confinement in clinical testing unit5  X5    
SnPP  infusion   X6    
Discharge from clinical testing unit    X7   
Prior/Concomitant medications  X X X  X 
Adverse events   X X  X 
Investigational product reconciliation      X 
 
1 Day 8 visit will occur (± 1) days and End of Study (EOS) visit will occur 28 ( ± 1) days after administration of SnPP. 
2 Baseline parameters  performed prior to dosing on Study Day 1. 
3 Two ECG’s will be performed on Study Day 1 : the first at Baseline (prior to infusion) and the second within 10 minutes of 
infusion completion.  
4 Blood samples for SnPP pharmacokinetic analysis will be assessed at baseline and 1, 2, 3, 4, 6, 8, 12, 18, and 24, hours (±15 
minutes) after start of infusion.   Additional biomarker samples will also be collected at 2, 4, 8, 12, 18 hours (±15 minutes) 
after start of SnPP.  Urinary tin excretion will be measured on a 24 -hour urine sample.  
5 Subjects will be confined in the clinical testing unit a minimum of 24 hours from the morning of Study Day 1 until after collection of the 24 -hour post -dose sample on Study Day 2.  
6 SnPP will be administered by infusion over 12 0-minutes  after Baseline ECG, vital signs and blood and urine samples are 
collected .  
7 Discharge from unit following evaluations and sample collection required on Study Day 2 
8 Measured fasting (nothing by mouth except water, coffee or tea, with or without milk and/or sugar, and essential medications only for a minimum of 8 hours prior to sample  collection at the clinic) .  
9 Parameters to be measured are detailed in Appendix 1.  
10 For women of childbearing potential using kits supplied by the laboratory  
11 Haptoglobin, Ferritin, Bilirubin, Hemopexin, IL -10, P21 and HO-1. 
12 Cystatin -C, IL -6, SnPP, total porphyrin,  Tin, Troponin I , albuminuria, Kidney Injury Molecule -1 (KIM -1), Neutrophil 
Gelatinase- Associated Lipocalin (NGAL),  N acetyl -beta-D-glucosaminidase (NAG),  (in addition to BUN/Cr which are part 
of the Serum Chemistry panel)  
13 Three measurements will be taken for the urinary safety biomarkers (albuminuria , Kidney Injury Molecule -1 (KIM -1), 
Neutrophil Gelatinase -Associated Lipocalin (NGAL), and N acetyl -beta-D-glucosaminidase (NAG) ), eGFR, and response 
biomarkers prior to dosing.  
 ** Day 14 safety evaluation will be conducted at the request of the DSMB after each cohort safety review  
  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 15 of 38 
6 INTRODUCTION 
6.1 Background Information 
Acute kidney injury (AKI) is an abrupt loss of kidney function in which the body accumulates 
waste products and is unable to maintain electrolyte, acid -base, and water balance [ Tögel 2014 ]. 
It is a major risk factor for morbidity, mortality, and  the development of chronic kidney disease 
(CKD) [ Goldberg 2009, Ishani 2009, Liangos 2006, Wald 2009, Xue 2006 ].  A meta -analysis of 
154 studies conducted worldwide in over 3.5 million subject s reported pooled incidence and 
mortality rates of AKI in hospitalized adult subject s of 21.6% and 23.9%, respectively 
[Susantitaphong 2013 ]. In cardiac surgery subject s, the incidence of postoperative AKI is 
approximately 30% and significantly increases the risk of death after cardiac surgery [ Rosner 
2006 ]. Progression to advanced- stage CKD  within 24 months occurs in approximately 15 to 20% 
of subject s who survive AKI [ Chawla 2012 ]. 
Many different types of exposure may cause AKI; however, the chance of developing AKI after 
exposure depends on a number of susceptibility factors that vary widely among individual 
subject s [Kellum 2013 ].  Sepsis, critical illness, circulatory shock, burns, trauma, cardiac surgery 
(particularly with cardiopulmonary bypass), major non-cardiac surgery, nephrotoxic drugs, 
radiocontrast agents, and poisonous plants and animals are all recognized as causes of 
AKI.   Susceptibility factors that increase a subject’s risk of developing AKI include dehydration 
or volume depletion, advanced age, female gender, Black race, chronic kidney disease, chronic 
disease (heart, lung, liver), diabetes mellitus, cancer, and anemia.  AKI can lead to a number of 
complications, including metabolic acidosis, hyperkalemia, uremia, changes in body fluid 
balance, an d effects on other organ systems, including need for dialysis and possibly death. 
People who have experienced AKI have an increased risk of developing chronic kidney disease 
possibly requiring dialysis in the future. The annual cost to the US health care s ystem is 
estimated at approximately $15B  [Silver 2017 ]. 
The diagnosis of AKI is based on the following criteria introduced by the Kidney Disease: 
Improving Global Outcomes (KDIGO) AKI Work Group in 2012 [ KDIGO 2012 ]: increase in 
serum creatinine ≥  0.3 mg/dL within 48 hours ; or increase in serum creatinine ≥  1.5 times 
baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume 
< 0.5 mL/kg/hour for 6 hours. The ma nagement of AKI is purely symptomatic, with the aim of 
limiting damage and preventing further loss of function. No pharmacologic therapy is approved 
for the treatment or prevention of AKI. 
It has long been recognized that after an initial ischemic or toxic  injury, the kidney develops 
marked resistance to subsequent damage [ Honda 1987, Zager 1984, Zager 1995a , Zager 1995b , 
Zager 1995c ]. This phenomenon, which is mediated in part by an upregulation of renal 
cytoprotective and anti- inflammatory stress proteins (e .g., heme oxygenase 1 [HO-1], ferritin, 
haptoglobin, hemopexin, alpha 1 antitrypsin, interleukin 10 [IL -10]), has been referred to as 
“ischemic preconditioning” or “acquired cytoresistance.” This phenomenon could be used in a 
clinical setting to preemptively protect organs, especially when a known insult is approaching. Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 16 of 38 
6.2 Study Drug  
A pharmacological intervention with the ability to stimulate the kidney’s natural protective 
pathways to prevent AKI would represent a significant medical advance. SnPP is under 
development as a prophylactic agent to induce cytoresistance in organs when a known insult is 
immin ent. The initial target for development is the kidneys and prevention of AKI.  However, 
the phenomenon of acquired cytoresistance is also relevant to other bodily organs such as the 
heart and liver, and will be the focus of extended development of SnPP in combination with 
other agents, more specifically, Iron Sucrose (FeS .) 
Stannous protoporphyrin, a potent competitive inhibitor of heme oxygenase activity, is not 
commercially available,  a 45 mg dose has been safely administered to healthy volunteers 
[Anderson 1986, Berglund 1988, Emtestam 1993 ], term newborns with hyperbilirubinemia 
[Kappas  1988 ], and adult subject s with hepatic dysfunction affecting heme metabolism or 
bilirubin conjugation [ Anderson 1986, Berglund 1990]  or porphyria [ Dover 1993, Galbraith 
1989 ]. 
6.3 Preclinical Experience  
Initial non -clinical pharmacology and toxicology studies have been conducted and are detailed in 
the Investigator’s Brochure.  Single -extended acute dose toxicity studies of intravenous SnPP 
demonstrated no- adverse -effect -levels of  10 mg/kg SnPP in the rat (human equivalent does of 96 
mg) and the dog (human equivalent dose of 324 mg).   
6.4 Clinical Experience 
Safety data from intravenous SnPP administration at doses up to 3 mg/kg has shown 
photosensitivity in subjects when exposed to sunlight or UV-A light following dosing [ Anderson 
1986 , Berglund 1990, Dover 1993, Galbraith 1989, Kap pas 1988 ].  No other adverse effects of 
SnPP administration have been consistently reported in the literature. 
7 STUDY OBJECTIVES  
7.1 Primary Objectives  
The primary objectives of the study are to evaluate:  
1. The safety and tolerability of SnPP in healthy volunteers and in subject s with stage 3 -4 
CKD.  
2. The effect of SnPP on biomarkers which are potential surrogates for cytoprotective activity in healthy volunteers and in subject s with stage 3 -4 CKD.  
3. To establish the optimal dose for testing in subject s at risk for developing AKI.  
4. To study the Pharmacokinetics of SnPP Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 17 of 38 
8 INFORMED CONSENT  
The investigator or designee will be responsible for obtaining a signed, written informed consent form (ICF) and providing a copy to each subject, legally authorized guardian, or a person with legal responsibility for the subject’s health care decisions prior to the performance of any clinical activities or procedures pursuant to this protocol. Subjects who are vision impaired may have the ICF read to them and their witnessed consent doc umented . Only the consent form approved by 
the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)  will be used . If 
English is NOT the subject’s primary language, the subject will be consented using an IRB-approved ICF in the requisite lang uage. This consent will be conducted by a member of the 
research team who is fluent in the language and thus able to answer any scientific or procedural questions raised by a non-English speaking subject. Subject identity should be confirmed by the presentation of a photo identification to ensure the correct individual is consented, screened, and enrolled (if eligible).  Only the PID, subject initials, and demographics will be recorded in the eCRF. If the subject name appears on any source document collected (e.g., hospital discharge summary), it must be removed from the document if the document will be viewed by the Sponsor or a sponsor-contracted study vendor not permitted access to subject identifying information. All study findings will be stored  in electronic databases. The subjects will give explicit written permission 
for representatives of the Sponsor, regulatory authorities, and the IRB to inspect their medical records to verify the information collected. Subjects will be informed that all pe rsonal 
information made available for inspection will be kept confidential to the extent permitted by all applicable state, local, and federal data protection/privacy laws and/or regulations and will not be made publicly available. If the results of the tr ial are published, the subject’s identity will remain 
confidential.   At study check -in to the study site, subjects will be advised not to share their study information 
with other subjects. 
9 STUDY POPULATION  
9.1 Healthy Volunteer (HV) 
9.1.1 HV Inclusion Criteria  
1. Male and female subject s age 18 to 80 years (inclusive, at time of signing the informed 
consent form [ ICF]). 
2. Body weight <125 kg. 
3. Able and willing to comply with all study procedures . 
4. Female subjects must be either post- menopausal for at least 1 year or su rgically sterile 
(tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until 28 days after study 
drug administration.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 18 of 38 
Male subject s with female partners of childbearing potential must agree to use a highly 
effective method of contraception from screening until 28 days after study drug administration. All fertile men with female partners of childbearing potential should be instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation.  
9.1.2 HV Exclusion Criteria  
1. Histor y of malignancy except carcinoma in situ in the cervix, early stage prostate cancer 
or non- melanoma skin cancers . Cancer free for less than 5 years  
2. Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to screening, whichever is longer. 
3. Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screening. 
4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study . 
5. Any significant acute or chronic diseases.  
6. Subjects with abnormal baseline liver tests or hepatitis serologies that suggest active infection. 
7. Regular use of drugs of abuse and/or positive findings on urinary drug screening.  
8. Current tobacco use and/or positive findings on urinary cotinine screening.  
9. Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects’ tasks associated with the protocol. 
10. Presence of any condition which, in the opinion of the inve stigator, places the subject at 
undue risk or potentially jeopardizes the quality of the data to be generated. 
11. Subjects with history of photosensitivity or active skin disease 
12. Known hypersensitivity or previous anaphylaxis to SnPP. 
9.2 CKD Subjects  
9.2.1 CKD Inclusion Criteria  
1. Male and female subject s age 18 to 80 years (inclusive, at time of ICF). 
2. Body weight <125 kg. 
3. Able and willing to comply with all study procedures . 
4. Female subjects must be either post- menopausal for at least 1 year or surgically sterile 
(tubal ligation, hysterectomy or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity from Screening until 28 days aft er study 
drug administration.  
Male subjects with female partners of childbearing potential must agree to use a highly effective method of contraception from screening until 28 days after study drug administration. All fertile men with female partners of c hildbearing potential should be Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 19 of 38 
instructed to contact the Investigator immediately if they suspect their partner might be pregnant (e.g., missed or late menstrual period) at any time during study participation . 
5. CKD stage 3 as determined by a GFR between 30-59 ml/min as estimated using the CKD- EPI equation.  
6. CKD stage 4 as determined by a GFR between 15-29 ml/min as estimated using the CKD- EPI equation.  
9.2.2 CKD Exclusion Criteria  
1. History of malignancy except carcinoma in situ in the cervix, early stage prostate cancer or non- melanoma skin cancers . Cancer free for less than 5 years.  
2. Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to screening, whichever is longer. 
3. Serum ferritin > 500 ng/ml or who have received IV iron within 28 days of screeni ng. 
4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study . 
5. Regular use of drugs of abuse and/or positive findings on urinary drug screening.  
6. Current tobacco use and/or positive findings on urinary cotinine screening.  
7. Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects’ tasks associated with the protocol 
8. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated. 
9. Subjects with abnormal baseline liver tests or hepatitis serologies that suggest active infection. 
10. Subjects with  CKD and not at their baseline of renal function and have significant acute 
or chronic illnesses . 
11. Subjects with history of photosensitivity or active skin disease 
12. Known hypersensitivity or previous anaphylaxis to SnPP. 
9.3 Study Design  
This is a Phase 1b, sing le-center, dose- escalating study to evaluate the safety, tolerability, PK 
and pharmacodynamic effect of SnPP in healthy volunteers and in subject s with stage 3 -4 CKD. 
The following biomarkers will be used as surrogate measures of protective activity: H aptoglobin, 
Ferritin, Bilirubin, Hemopexin, IL-10, P21 and HO -1. 
Screening data will be reviewed to determine subject eligibility. Subjects  who meet all inclusion 
criteria and none of the exclusion criteria are eligible to be enrolled into the study.  A baseline for safety and response biomarkers will be established by taking three measurements between screening and prior to dosing.  
The study is designed as follows: 
• A screening period with baseline evaluations for study eligibility.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 20 of 38 
• If subjects meet eligibility criteria, they will receive SnPP by direct “push” infusion over a 120-minute period on SD  1.  
• Subjects will stay in the clinic for the initial 24 hours after administration of SnPP and will be discharged on SD  2 if no safety issues appear.  
• The study will initially be dose- escalating in 3 groups of 6 healthy volunteers each, for a total of 
18 healthy volunteers, evaluating escalating single dose of SnPP starting with a dose of 9 mg SnPP, followed by 27 mg  SnPP, and 90 mg SnPP.  Dose -escalation from one dose level to the 
next will only be allowed after a careful review of the safety , tolerability and PK data from the 
prior dose  group as determined by the D ata and  Safety Monitoring Board (DSMB). 
• After a careful review of the safety , tolerability and PK data from all  dose groups from the 
healthy volunteer cohorts, the D ata and  Safety Monitoring Board (DSMB) will determine 
whether to proceed to the CKD cohorts. If the determination by the DSMB allows to proceed to the CKD cohorts, subjects with stage 3 CKD will be in 2 groups of 6 each, for a total of 12 subjects, evaluating escalating single dose of SnPP starting with a dose of 27 mg SnPP followed by 90 mg SnPP.  Dose -escalation from one dose level to the next will only be allowed aft er a 
careful review of the safety , tolerability and PK data from the prior dose group as determined by 
the D ata &  Safety Monitoring Board (DSMB).  
• After a careful review of the safety , tolerability and PK data from all  dose groups from the stage 3 
CKD cohor ts, the D ata and  Safety Monitoring Board (DSMB) will determine whether to proceed 
to the stage 4 CKD cohorts. If the determination by the DSMB allows to proceed to the stage 4 CKD cohorts, subjects with stage 4 CKD will be in 2 groups of 6 each, for a total of 12 subjects, evaluating escalating single dose of SnPP starting with a dose of 27 mg SnPP followed by 90 mg SnPP.  Dose -escalation from one dose level to the next will only be allowed after a careful review 
of the safety , tolerability and PK data from the prior dose  group as determined by the D ata and  
Safety Monitoring Board (DSMB).
 
• The infusions will be given over a 120-minute period using a syringe pump.  
• Subjects will be followed for 28 days after the dose of SnPP. Response and Safety biomarkers will be assessed at baseline and (2, 4, 8, 12, 18, response biomarkers only) 24, 48, 72, 96 and 168 hours after study drug administration. Safety will be assessed for up to 28 days after study drug administration.  Urine samples will be collected  and 
centrifuged and analyzed for subject responsiveness to SnPP therapy.  
• Blood samples for pharmacokinetic analysis will be collected at baseline and 1, 2, 3, 4, 6, 8, 12, 18 and 24 h post start of infusion. 
• Urinary excretion of SnPP will be assessed in  a 24-hour urine sample by measuring tin in 
urine 
• Total study duration will be up to 29 days per subject.  
9.3.1 Stopping Rules  
There are no pre-established stopping rules for the study.   
9.4 Recordkeeping and Monitoring  
All subject data will be reported in the electr onic data capture (EDC) system with the exception 
of the laboratory reports, which will be uploaded by electronic transfer by the laboratory. All 
original source documents should be available for periodic monitoring and/or retrieval by a Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 21 of 38 
Sponsor representative designee. The investigator is responsible for the accuracy of all data entered in the electronic case report forms ( eCRFs ) and for the timely completion of the 
electron ic case report forms ( eCRFs ). The supporting documentation will be mainta ined at the 
site for a minimum of either: 
1. Two (2) years following notification by Renibus Therapeutics, Inc.  to the FDA of the 
termination of the entire investigation.  
The Sponsor must be contacted and give written authorization prior to any study records being destroyed at investigative sites.  
This study will be conducted in compliance with Good Clinical Practice (GCP), which includes the Sponsor and Institutional Review Board  (IRB) -approved protocol and ICF and the FDA and 
International Conference on Harmonisation ( ICH) regulatory guidelines and requirements. No 
changes will be made without prior approval unless it is imperative for subject safety . Any such 
departures from the protocol will be reported immediately to the Sponsor and relevant IRB. All subj ects’ medical records and study- related documents will be made available to the Sponsor 
for regular monitoring and audits as well as to the IRB and FDA or other governmental agency with oversight or compliance responsibilities for assuring subject rights a nd welfare.  
9.5 Investigational Supplies 
Subjects  will be dosed with open- label SnPP. 
9.5.1 Study Drug Description 
The investigational product is a mixture of Stannous protoporphyrin IX dichloride (SnPP) in a solution of sodium hydroxide The term investigational product refers to SnPP. 9.5.2 Packaging 
SnPP will be packaged and labeled in filled vials of 5 ml at P atheon, Inc.. SnPP will be packaged 
in a clear vial protected from light . 
Following receipt of Form FDA 1572 and IRB approval for a given site, investigational product will be sent to the study site.  9.5.3 Investigational P roduct  Dispensing  
All investigational product will be dispensed by designated and trained site pharmacy staff.  9.5.4 Dosage Preparation and Administration 
The vials of SnPP will be directly infused over a 120-minute period, further instructions will be included in the Pharmacy Manual.  Total infusion time will be 120 (± 5) minutes as detailed in the Pharmacy Manual.  
Subjects will be o bserved for signs and symptoms of hypersensitivity during and after 
administration for at least 30 minutes and until clinically stable following completion of each administration. SnPP will only be administer ed when personnel and therapies are immediately 
availab le for the treatment of serious hypersensitivity reactions.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 22 of 38 
9.5.5 Storage Requirements  
The investigational product should be stored at controlled room temperature conditions (defined as 20 - 25°C/68 - 77°F with excursions of less than 24 consecutive hours permitted between 15 - 30°C/59 - 86°F)  and protected from light. 
9.5.6 Investigational Product Accountability 
The i nvestigator or designee is responsible for maintaining accurate records accounting for the 
receipt, dispensing, and final disposition of all investigatio nal products using the appropriate 
investigational product logs provided by Renibus Therapeutics, Inc.  
9.5.7 Retrieval and Destruction  
Periodically throughout the study, sites will perform investigational product reconciliation on a per-subject basis . The Renibus site monitor will review the log and o nce any discrepancies have 
been resolved , authorize destruction/disposition of the supplies associated with a given subject 
by signing the reconciliation log and will witness the destruction/disposition . 
9.6 Study Visits  
9.6.1 General Information 
• All recorded clock times should utilize a 24-hour clock. 
• In accordance with the clinical site ’s standard operating procedures, an intravenous 
catheter or a butterfly needle (of a sufficient gau ge to avoid sample hemolysis) may be 
inser ted for the purpose of collection of blood samples. Alternatively, the site preference 
may be to use direct venipuncture for the purpose of collection of blood samples. Either method is acceptable.  
• There are no dietary restrictions in this study. Subjects should continue to eat their normal diet.  
• Subjects will be encouraged to remain well hydrated during the study to promote sample collection.  
• Blood samples for Chemistry, Hematology, biomarkers and pharmacokinetic analysis will be collected into the appropriate collection tubes and processed in accordance with 
the instructions specified in the laboratory manual.  
• The ICF must be signed before any of the Screening or Study procedures are performed. 
9.6.2 Screening  (Within 14 Days Prior to Study Day 1) 
1. Subject s will arrive at the clinical testing unit in the morning after fasting (defined as 
nothing by mouth except water) for at least 8 hours prior to the collection of any blood samples.  
2. Eligibility will be confirmed.  
3. Demographic characteristics and medical his tory will be obtained. 
4. Physical examination (including height and weight), vital signs (after sitting ≥  5 minutes), 
and 12- lead ECG (after sitting ≥  5 minutes) will be performed.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 23 of 38 
5. Blood and urine will be collected for clinical laboratory tests ( Appendix 1) and 
drug/alcohol/cotinine screen. 
6. For women of childbearing potential, urine pregnancy test will be performed. 
7. Eligible subjects will return to the clinical testing unit within 14 days for confinement and dosing. 
8. An ad ditional blood and urine sample will be taken between screening and prior to dosing 
on Study Day 1 in order to establish a baseline measurement for safety and efficacy biomarkers (a total of three measurements).  
9.6.3 Study Day 1 
1. Subjects will arrive at the clin ic at 8:00am (± 60 minutes). 
2. All eligibility criteria will be assessed . 
For CKD subjects, subjects whose GFR value does not meet the inclusion criteria may be re- screened 2 more time s during the trial. If the ICF has been signed within 30 days 
and there ar e no new revisions, a new ICF is not necessary. If a subject is re- screened, 
the subject will be given a new screening number in the eCRF system and source documents.  
3. If all eligibility criteria are met, the following Baseline samples will be collected  
(Appendix 1): 
• Blood samples for standard assessment of hematology and serum chemistry. 
• Blood samples for measurement of response biomarkers ( Haptoglobin, F erritin, 
Bilirubin, H emopexin, IL -10, P21 and HO-1). 
• Blood samples for measurement of Safety biomarkers ( Tin, Total Porphyrins, IL-6, 
Troponin I  and Cystatin -C). 
• Blood samples for measurement of SnPP. 
• Urine for s tandard assessment of urinalysis parameters  and safety biomarkers 
(albuminuria , Cystatin -C, 
 Kidney Injury Molecule- 1 (KIM -1), Neutrophil 
Gelatinase- Associated Lipocalin  (NGAL),  and NAG) . 
• Urine samples for measurement of response biomarkers (Hemopexin , Ferritin, P 21 
and HO-1) , and for urinary clearance of SnPP .  Urine samples will be collected and 
centrifuged and analyzed for subject responsiveness to SnPP therapy. 
2. A Baseline ECG will be performed  (Section 9.8.1 ). 
3. A full physical examination including height, weight, and vital signs will be performed (Sections 9.8.3 and 9.8.4 ). 
4. Medical history  and prior/ concomitant medication information will be collected . (Section  
9.8.2) 
5. Subjects who meet all inclusion/exclusion criteria will be enrolled into the Study and the following procedures will take place:  
• The dose of SnPP will be administered in the clinic as  a “push,” direct  infusion over a 
120 ± 5-minute period.  Food may be given after the infusion.   Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 24 of 38 
Observe for signs and symptoms of hypersensitivity during and after administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.  
 Should a subject experience nausea during or after infusio n, the investigator 
may order Ondansetron (Zofran®) per its label instructions . Zofran may also be 
given prophylactically if at lower doses nausea is observed in subjects.  
• Patients will be advised on other interventions necessary to mitigate the risk of phototoxicity such as wearing a hat, sunglasses, long sleeve shirts and sunscreen  
with an SPF
≥30, when appropriate, . 
• A post-infusion ECG will be performed 10 minutes (± 15 minutes) after the end of the infusion. 
• The clinic staff will solicit any adverse even ts. 
• Response biomarker samples will be collected at 2, 4, 8, 12, and 18 hours (± 15 minutes) after the start of the infusion. 
• Blood samples for pharmacokinetic analysis will be collected at 1, 2, 3, 4, 6, 8, 12, 18 and 24 hours (± 15 minutes) after the start of the infusion . 
• Lunch and dinner will be provided  by the clinic . 
9.6.4 Study Day 2 
The following procedures will be done at 24 hours (± 15 minutes) after dosing:  
1. Blood samples for standard assessment of clinical chemistry, hematolo gy, and safety and 
respo nse biomarkers will be collected ( Appendix 1).  
2. Blood samples for pharmacokinetic analysis will be collected.  
3. Urine samples for standard assessment of urinalysis parameters and response biomarkers 
will be collected  (Appendix 1).  
4. The clinic staff will solicit any adverse events and note any changes in concomitant medications . 
5. The subject will be discharged from the clinic per site disch arge procedures.  
9.6.5 Study Day s 3,4,5,8 (Day 8 ± 1 day) 
1. Subjects will arrive at the clinic at 8:00am (± 60 minutes).  
2. Blood samples for standard assessment of clinical chemistry, hematology, and safety and response biomarkers will be collected ( Appendix 1).  
3. Urine samples for standard assessment of urinalysis parameters and response biomarkers 
will be collected  (Appendix 1).  
4. A urine pregnancy test will be performed if the subject is a woman of childbearing potential at Day 8 . Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 25 of 38 
5. The clinic staff will solicit any adverse events and note any chan ges in concomitant 
medications since the last visit.  
9.6.6 Study Day 14 Study Day 14 safety review will be conducted at the request of the DSMB after the data assessment from each cohort.  
9.6.7 Study Day 29/End of Study Visit  (28 ± 1 days following the SnPP  dose) 
1. Subjects will arrive at the clinic at 8:00am (± 60 minutes).  
2. Blood samples for standard assessment of clinical chemistry, hematology, and safety biomarkers will be collected ( Appendix 1).  
3. Urine samples for standard assessment of urinalysis parameters and safety biomarkers  
will be collected  (Appendix 1).  
4. A full physical examination including weight and vital signs will be performed ( Sections 
9.8.3 and 9.8.4).   
5. The clinic staff will solicit any adverse events and note any changes in concomitant medications since the last visit.  
6. A urine pregnancy test will be performed if the subject is a woman of childbearing potential. 
9.7 Clinical Laboratory Evaluations 
All samples for clinical laboratory evaluations will be collected under fasting conditions, defined as nothing by mouth except water, and essential medications only ( for CKD patients) for a 
minimum of 8 hours prior to collection of the samples.  9.7.1 Blood C hemistry , Hematology, Pharmacokinetic and Response  biomarker Samples  
The c hemistry , hematology and response biomarker parameters to be evaluated during the study 
are presented in Appendix 1. Detailed instructions regarding sample col lection and processi ng 
are provided in the laboratory m anual . Collection times are summarized in the Events Schedules  
(Section 5 and Section  9.6).  
9.7.2 Urine Samples  
The urine parameters , including SnPP urinary excretion,  and response biomarkers to be 
evaluated during the Study  are presented in Appendix 1. Detailed instructions regarding sample 
collection and processing are provided in the laboratory m anual . Collection times are found in 
the Events Schedules ( Section 5 and Section  9.6). All urine s amples will be analyzed by the 
laboratory, except for urine pregnancy tests for women of childbearing potential. All women of childbearing potential (defined as not surgically sterile nor postmenopausal for at least 2 years) will have a urine pregnancy test performed at the clinic as par t of the screening 
procedure prior to any investigational product administration and at an End of Study using the pregnancy kit supplied by the l aboratory .  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 26 of 38 
9.8 Clinical Procedures and Observations  
The research clinic will follow its own standard operating pro cedures for the daily ongoing 
monitoring of subjects while subjects are in the clinic  (e.g. pulse, O 2 saturation, etc.) . Subjects 
will be monitored for any adverse events occurring at any time throughout the study. 9.8.1 ECG  
ECGs will utilize a 12 -lead recording . Collection times are summarized in the Events Schedules 
(Section 5 and Section  9.6). E CG results will be assessed by the investigator/sub- investigator .  
9.8.2 Concomitant Medications  
All concomitant medications taken by the subject from 30 days prior to Study Day 1 through the end of study (28 [ ± 1] days after the dose of investigational product) will be recorded.  
9.8.3 Physical Examination 
A full physical examination , including height (Study Day 1 only) and weight (weighed on the 
same scale in the same state of dress), will be conducted  at Day 1 and at end of the study. 
Collection times are summarized in the Events Schedules ( Section  5 and Section  9.6).  
All physical examinations are to be performed by the investigator/sub -investigator or designee 
whose license permits the performing of physical examinations.  
9.8.4 Vital Sig ns 
Blood pressure (systolic and diastolic), pulse, and body temperature will be measured before investigational product is administered and after the subject has been in a sitting position for ≥  5 
minutes . Collection times are summarized in the Events Schedules ( Section  5 and Section  9.6).  
9.8.5 Meals and Dose Administration 
There are no dietary restrictions in this study. Subjects should continue to eat their normal diet.  Breakfast may be eaten before or after the infusion of SnPP on Study Day 1. 9.8.6 Prohibited Medications  
Medications which can cause photosensitivity are prohibited for subjects in the Study.  Oral iron medication may be taken prior to screening but must be discontinued upon enrollment. 
10 ADVERSE EVENT REPORTING  
All adverse events  will be recorded on the designated study eCRF for each subject beginning 
with the first administration of investigational product and ending with the date of the end of study treatment follow -up. Any unresolved adverse events  will be followed by the investigator 
until event resolution, the subject is lost to follow-up, the adverse event  is otherwise explained or 
not considered clinically significant by the investigator.  
10.1 Investigator Reporting Requirements  
The investigator must immediately report (within 24 hours by telephone and followed by a written report sent by fax or e- mail) all serious adverse events to Renibus Therapeutics, Inc. 
regardless of whether the investigator believes that they are drug related, including those e vents Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 27 of 38 
listed in the protocol as anticipated to occur in the study population independent of drug exposure (see Section 10.2).  These serious advers e events must be reported to: 
Bhupinder Singh, MD, FASN, FNKF  
 Medical Monitor  Renibus Therapeutics, Inc 
950 E State Highway 114, Suite 160 Southlake, TX 76092 
Cell:   (480) 220-7084 
Fax  (817) 549-1254 
E-mail:   medicalmonitor@renibus.com 
Because the investigator is knowledgeable about the human subject (e.g., medical history, concomitant medications), administers the investigational drug, monitors the subject’s response to the drug, is aware of the subject’s clinical state and thus may be sensitive to  distinctions 
between events due to an underlying disease process versus events that may be drug- related, and 
may have observed the event, the investigator must include an assessment of causality (i.e., whether there is a reasonable possibility that the dr ug caused the event) in the report to Renibus 
Therapeutics, Inc Copies of each report to Renibus Therapeutics, Inc. will be kept in the 
investigator’s study file.  
The investigator is responsible for complying with their IRB’s requirements for reporting serious 
adverse events . Any expedited safety report (i .e., serious unexpected suspected adverse reaction) 
received from Renibus Therapeutics, Inc. should be submitted to the IRB. Copies of each report 
and documentation of IRB notification will be kept in the investigator’s study file.  
The investigator must record non-serious adverse events in the eCRF and report them to Sponsor according to the timetable for reporting (e .g., end of study) . The investigator’s assessment of 
causality is not required for non- serious adverse events. 
10.2 Definitions  
Adverse Event:   Adverse event means any untoward medical occurrence associated with the use 
of a drug in humans, whether or not considered drug related. An adverse event  can be any 
unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. 
Adverse Reaction:   Adverse reaction  means any adverse event  definitely caused by the drug. 
Suspected Adverse Reaction:  Suspected adverse reaction  means any adverse event for which 
there is a “reasonable possibility” (i .e., evidence indefinite but suggests a causal relationship 
between the drug and the adverse event ) that the drug caused the adverse event. By definition , a 
suspected adverse reaction is identical to the definition of adverse drug reaction per ICH E2A. Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 28 of 38 
Examples that would suggest a causal relationship: 
• A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., a ngioedema, hepatic injury, Stevens -Johnson Syndrome) 
• One or more occurrences of an event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug (e.g., tendon rupture) 
• An aggregate analysis of specific events observed in a clinical trial (e.g., known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the drug treatment group than in a concurrent or historical control group. 
Unexpected Adverse Event or Unexpected Adverse Reaction:  An adverse event  or adverse 
reaction  is considered “unexpected” if it is not listed in the investigator bro chure or is not listed 
at the specificity or severity that has been observed.  
Adverse event s or adverse reactions that are mentioned as occurring with a class of drugs or as 
anticipated from the pharmacological properties of the drug will be considered “unexpected” if they are not specifically mentioned as occurring with the particular drug under investigation. Until the investigator brochure is updated to include a new serious suspected adverse reaction , 
subsequent occurrences of similar serious suspected adverse reactions  must be submitted 
expeditiously to FDA in IND Safety Reports  and to other appropriate regulatory authorities in 
countries other than the US in an Individual Case Safety Report (ICSR) or using a Council for International Organizations of M edical Sciences (CIOMS) I form, as appropriate. 
Serious Adverse Event or Serious Adverse Reaction:  An adverse event  or adverse reaction  is 
considered “serious” if, in the view of either the investigator or Sponsor, it results in any of the following outcomes:  
• Death  
• A life -threatening adverse event  
• In subject hospitalization or prolongation of existing hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions 
• A congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical inte rvention to prevent one of the 
outcomes listed in this definition.  
If either the investigator or Sponsor believes that the event is serious, it must be evaluated by the Sponsor for expedited reporting to regulatory authorities. Life-Threatening Adverse Event or Life- Threatening Adverse Reaction:  An adverse event  or 
suspected adverse reaction  is considered “life-threatening” if, in the view of either the 
investigator or Renibus , its occurrence places the subject at immediate risk of death.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 29 of 38 
Serious Unexpected Suspected Adverse Reaction:  An adverse event for which there is a reasonable possibility that the drug caused the adverse event, and it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed, and it results in any of the serious outcomes listed above. This criterion is consistent with the concepts of FDA 21  Code of F ederal Regulation (CFR) 312 and the ICH E2A Guideline for expedited 
safety reports . 
The Sponsor must notify the appropriate regulato ry authority(ies) and all participating 
investigators in an expedited safety report (e.g., IND Safety Report or ICRS) of potentially 
serious risks from clinical trials or any other source (i.e., a serious unexpected suspected adverse reaction), as soon as possible, but no later than 15 calendar days after Renibus Therapeutics, Inc.  
receives the safety information and determines that the information qualifies for reporting.  
During the course of drug development, the Sponsor may become aware of new safety information from a variety of sources and will decide if an individual case of a serious and unexpected adverse event meets the criteria for reporting to regulatory authorities. If the adverse event does not meet all criteria (i .e., reasonable possibility of causality, serious and 
unexpected), it should not be submitted as an expedited s afety r eport.  
Any unexpected fatal or life- threatening suspected adverse reaction must be reported to 
regulatory authorities no later than 7 calendar days after Renibus Therapeutics, Inc. receives the safety information. 
10.3 Breaking the Blind  
Not applicable as this is an open label study. 
11  STATISTICAL CONSIDERATIONS  
This section outlines the nature and rationale for the statistical methods to be used for the analysis of the data from the study. A separate Statistical Analysis Plan (SAP) will describe data 
handling and statistical techniques in full detail.  
11.1 Study Populations  
All subject s who receive study medication will be included in the safety and PD analyses. All 
subject s who receive study medication and provided sufficient and valid serum SnPP 
concentration data to allow the determination of PK parameters will be considered as potential PK evaluable subject s. No imputation will be used for missing data. 
11.2 Demographic and Baseline Characteristics  
Demographic and baseline variables that will be summarized by dose group include:  
• Demographics   
• Medical history  
• Complete PE  
• Efficacy and Safety variables including vital signs and laboratory tests, including chemistry, hematology, and ur inalysis obtained at Screening.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 30 of 38 
11.3 Analysis of Efficacy Endpoint s 
Descriptive statistics will be used to summarize Response biomarker results at baseline, each 
visit, and the change from baseline for each visit. Percent change from baseline will be analyzed using the mixed model for repeated measures (MMRM). In this analysis, percent change from baseline at each post treatment time point will 
be the response variable; treatment, visit, and treatment -by-visit interaction as fixed factors , 
patient as repeated me asure unit over visits , and baseline as covariate. The between -group 
comparison will be performed using the simple contrast at 2, 4, 8, 12, 18, 24, 48, 72, 96 and 168 hours post-dosing.  In addition to the percent changes from baseline, absolute change from baseline will also be 
analyzed using MMRM. Moreover, a responder analysis will also be considered. The 
responder definition and its appropriate analysis methodology will be detailed in the statistical analysis plan (SAP) for the study. Exploratory analysis using Cochran- Mantel -Haenszel test 
stratified by baseline or primary diagnosis will be carried out.  
11.4 Analysis of Pharmacodynamic/ Safety  Endpoints  
The evaluation of safety will include adverse events, clinical laboratory parameters, vital signs, physic al examinations, and ECGs.  
The principle of treatment emergence will be employed for the analysis of adverse event data. A Treatment emergent adverse event (TEAE) is defined to be any event that occurs during the observation period of the study and was not present at baseline, or exacerbation of a condition present at baseline.   
TEAEs will be classified by the Medical Dictionary for Regulatory Activities (MedDRA). The type, incidence, timing (onset, duration), relationship, and severity of adverse events will be reported for treatment -emergent and serious adverse events. Reasons for withdrawal due to 
adverse events will also be reported.   Descriptive statistics, including mean, mean change from baseline, standard deviation, minimum, maximum, and median , will be presented for laboratory parameters, vital signs, and ECG 
parameters. The numbers and percentages of subjects with treatment-emergent laboratory, vital sign, and ECG values that meet Sponsor- defined potentially clinically significant criteria will b e 
summarized. Categorical (low, normal, and high relative to the normal range) shifts from baseline will be summarized with the number and percentage of subjects for laboratory parameters . 
All safety data will be displayed in listings.  
11.5 Analysis of Pharmacokinetic  (PK)  Data  
Pharmacokinetic (PK) parameters will be calculated for each subject and summarized by treatment group . PK profiles in which the pre-dose concentration is > 5% of the corresponding 
C
max (and therefore greater than the lower limit of quanti fication [L LOQ ]) will be excluded from 
all descriptive statistics and statistical analyses.  
For the PK analysis performed, actual blood sampling times will be used in all PK  analyses. 
Protocol- specified times will be used to calculate mean plasma or serum concentrations for Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 31 of 38 
tabular and graphical displays. All PK  calculations and generation of individual subject plasma 
or serum concentration versus time graphs will be performed using SAS®. 
PK parameters will be calculated using non- compartmental analysis. The maximum serum 
concentration (C max) and time to maximum serum concentration (Tmax) will be obtained directly 
from the data. The elimination rate constant (λz), elimination half -life (T ½), area under the 
concentration -time curve from time 0 to time t (AUC [0-t]) and area under the concentration- time 
curve from time 0 to infinity (AUC [0-inf]), clearance (CL), and volume of distribution (Vz) will be 
calculated for each subject and summarized by tre atment group.. Only plasma samples with 
concentrations ≥ L LOQ will be used in the PK  analysis. Plasma concentrations < L LOQ will be 
taken as 0 for the calculation of the descriptive statistics at each sampling time. For the PK  
analysis, plasma concentratio ns < L LOQ that occur from pre -dose to the first concentration 
≥ LLOQ will be taken as 0  and those that occur thereafter will be taken as missing.  
The first dose escalation, from 9 mg to 27 mg, will be based on assuming a dose -proportional 
increase in Cmax  and AUC and will use the maximum values across the first cohort. The 
subsequent decisions to escalate to the next dose level will be based on the available pharmacokinetic exposure data from the previous dose cohort(s) and compared with the exposure level s at the NOAEL established in the acute dose toxicity study in male and female Sprague 
Dawley rats.  The dose escalation decision will utilize best available modelling practices, i.e. fitting the power model to the individual subject Cmax and AUC vs. dose.  A dose will not be 
administered that would result in an upper 95
th percentile for the model -predicted Cmax and AUC 
values exceeding 39,250 ng/mL and 209,500 hr.ng/mL (mean of males and females), respectively. These values were the observed values at the NOAEL of 10 mg/kg/day in the GLP toxicology 
study performed in Sprague Dawley rats.   
11.6 Sample Size Calculations  
No formal sample size calculation has been performed for the study. However, it is believed that 4 subject s per dose group will be adequate to establish POC based on biomarker response and 
identify an optimal dose for further testing, recognizing that a battery of different surrogate biomarkers will be evaluated . 
11.7 Interim Analysis  
No interim analysis is  planned.   
12 WITHDRAWAL FROM STUDY  
Every reaso nable effort should be made to maintain protocol compliance and participation in the 
study. Should a subject withdraw or be prematurely terminated from the study for any reason, the reason for early study withdrawal will be recorded . If withdrawal is the r esult of a serious Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 32 of 38 
adverse reaction , the subject will be followed until the condition has resolved, as determined by 
the investigator.  
The investigator or Sponsor may withdraw any subject at any time for medical reasons or for administrative reasons (i.e., subjects unable or unwilling to comply with the protocol). If so, the subject will be censored at time of withdrawal and , if possible, a final evaluation (E nd of Study 
procedures) will be made . All treated subjects (those who have received at least 1 dose of 
investigational product) will be included in the ITT and s afety analyses.  
In the unlikely event the Sponsor or FDA should determine it is appropriate to terminate the study early, every effort will be made for transitioning subjects with minimal disruption to the subject and investigator. The IRB will be notified of termination, and reason(s) and procedures 
for follow -up of research subjects will be developed by the study physician in consultation with 
the Sponsor and IRB. 
13  DATA MANAGEMENT  
The standard procedures for handling and processing records will be followed as per GCP and the data management standard operating procedures of the contract research organization (CRO). A comprehe nsive Data Management Plan  will be developed and approved by a representative of 
the Data Management CRO and the Sponsor. 
13.1 Database Lock 
The database will be locked in order to protect write access after the following preconditions are fulfilled: 
• All data are entered in the database  
• All data queries have been resolved to the satisfaction of the Lead Biostatistician  
• All decisions have been made regarding all protocol violators and ITT population exclusions 
• The eCRF will be signed off/approved by the Site Investigator 
• Written authorizations to lock the database are obtained from Renibus Clinical Data Management and the Chief Scientific Officer . 
14 ETHICAL CONSIDERATIONS  
14.1 Ethical Conduct of the Study  
The study will be conducted in accordance with United S tates Title 21 CFR  and the ICH E6 (R1) 
Guidelines of Good Clinical Practice . The Declaration of Helsinki and its most recent updates 
(Seoul, 2008) will be observed. The investigator will provide the Sponsor/designee with documentation of IRB approval of the 
protocol and the sample informed consent document before the study may begin at the investigative site . The IRB will review the protocol as required.  
The investigator will supply the following to the IRB: Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 33 of 38 
• The current Investigator’s Brochur e and updates  
• Study protocol and amendments 
• Informed consent and assent document and updates 
• Relevant curricula vitae  
• Safety alerts 
• Serious adverse reaction  reports 
The investigator must provide the following documentation to the Sponsor or designee:  
• The IRB original approval of the protocol and the informed consent, and re-approval of 
the study (annual or semi-annual, per IRB guidelines)  
• The IRB approvals of any revisions to the informed consent document or amendments to 
the protocol 
• All other documents that are required by local regulatory authorities 
14.2 Regulatory Considerations 
After reading the protocol, each investigator/sub-investigator will sign a protocol signature page 
and return a copy of the signed page to the Sponsor/ designee, while maintaining the  original at 
the site.  
14.3 Protocol Amendments and Study Termination 
The IRB must be informed and give approval for any amendments likely to affect the safety of 
the subjects or the conduct of the study. The IRB must be advised in writing of the study’s completion or early termination and a copy of 
the notification must be provided to the Sponsor. 
14.4 Safety Monitoring 
The Sponsor’s Medical Monitor and will monitor safety data throughout the course of the study. Renibus Drug Safety, or their designee, will expedite to the regulatory authorities only the suspected adverse reactions that are product -related and unexpected in accordance with FDA 21  
CFR  312, FDA draft guidance (Sept 2010) on Safety Reporting Requirements for INDs, and the 
ICH E2A guideline. 
14.5 Quality Control and Quality Assurance 
By signing this protocol, the Sponsor agrees to be responsible for implementing and maintaining quality control and quality assurance systems with written standard operating procedures to ensure that the study is conducted and data are generated, documented, and reported in compliance with the protocol, accepted standards of GCPs, and all applicable federal, state, and local laws, rules and regulations relating to the conduct of the clinical study.  
By signing this protocol, the investigator agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol, generally accepted standards of GCP, and all applicable federal, state, and local laws, rules and regulations relating to the conduct of the clinical study.  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 34 of 38 
The investigator also agrees to allow monitoring, audits, IRB review and regulatory agency 
inspection of study-related documents and procedures and provide for direct access to all study-related source data and documents . Investigators will b e given notice before a quality assurance 
audit occurs. The investigator shall prepare and maintain complete and accurate study documentation in compliance with GCP standards and applicable federal, state, and local laws, rules and regulations, and promptly submit to the Sponsor all forms and reports required by this protocol following completion or termination of the clinical study or as otherwise required due to any agreement with the Sponsor. 
15 GENERAL CONSIDERATIONS  
15.1 Discontinuation of the Study  
The Sponsor reserves the right to discontinue this study or investigator’s participation in this study for safety or administrative reasons at any time.   Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 35 of 38 
16 AGREEMENT WITH PROTOCOL  
I have read this protocol and agree to conduct this clinical study as outlined her ein. I will ensure 
that all sub -investigators and other study staff members have read and understand all aspects of 
this protocol. I agree to cooperate fully with Renibus Therapeutics, Inc. and its appointed Contract  Research Organization s (CRO s) during the study . I will adhere to all Food and Drug 
Administration (FDA), International Conference on Harmonisation (ICH), revised Declaration of Helsinki (2008) and other applicable regulations and guidelines regarding clinical trials on a study drug during and after study completion. Principal Investigator: 
Printed Name:   
Signature:   
Date:   
Protocol REN-003 A Phase 1b dose- escalating study with Stannous Protoporphyrin ( SnPP), in healthy volunteers 
and subject s with chronic kidney disease stage 3- 4. 
Original Protocol: 25 March  2019 
  Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 36 of 38 
17 REFERENCES  
Anderson KE, Simionatto CS, Drummond GS, Kappas A.   Disposition of tin -protoporphyrin 
and suppression of hyperbilirubinemia in humans.  Clin Pharmacol Ther.   1986;39(5):510-20. 
 
Berglund L, Angelin B, Blomstrand  R, Drummond G, Kappas A.   Sn-protoporphyrin lowers 
serum bilirubin levels, decreases biliary bilirubin output, enhances biliary heme excretion and 
potently inhibits hepatic heme oxygenase activity in normal human subjects. Hepatology. 
1988;8(3):625-31. 
 
Berglund L, Angelin B, Hultcrantz R, et al.   Studies with the heme oxygenase inhibitor 
Sn-protoporphyrin in subject s with primary biliary cirrhosis and idiopathic haemochromatosis. 
Gut. 1990;31:899 -904. 
 
Chawla L, Kimmel P. Acute kidney injury and chronic kidney disease: an integrated clinical 
syndrome. Kidney Int. 2012;82:516 -24. 
 
Dover SB, Moore MR, Fitzsimmons EJ, Graham A, McColl KE. Tin protoporphyrin prolongs 
the biochemical remission produced by heme arginate in acute hepatic porphyria. 
Gastroenter ology. 1993 Aug;105(2):500 -6. 
 
Emtestam L, Angelin B, Berglund L, Drummond GS, Kappas A.  Photodynamic properties of 
Sn-protoporphyrin: clinical investigations and phototesting in human subjects. Acta Derm 
Venereol. 1993;73(1):26 -30. 
 
Galbraith RA, Kappa s A.  Pharmacokinetics of tin -mesoporphyrin in man and the effects of 
tin-chelated porphyrins on hyperexcretion of heme pathway precursors in subjects with acute 
inducible porphyria. Hepatology. 1989;9:882 -8. 
 
Goldberg A, Kogan E, Hammerman H, Markiewicz W, Aronson D. The impact of transient 
and persistent acute kidney injury on long- term outcomes after acute myocardial 
infarction.   Kidney Int. 2009;76:900 -6. 
 
Honda IK, Hishida A, Ikuma K, Yonemura K. Acquired resistance to acute renal failure: 
editorial review.   Kidney Int.   1987;31:1233 -8. 
 
Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among 
elderly.   J Am Soc Nephrol. 2009;20:223 -8. 
 
Kappas A, Drummond GS, Ma nola T, Petmezaki S, Valaes T. Sn -protoporphyrin use in the 
management of hyperbilirubinemia in term newborns with direct Coombs -positive ABO 
incompatibility. Pediatrics. 1988;81(4):485 -97. 
 
Kellum J, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: A 
KIDGO summary (part 1). Crit Care. 2013;17(1):204.  
 Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 37 of 38 
KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury.   Kidney 
Int Supp.   2012;17:1 -138. 
 
Liangos O, Wald R, O’Bell JW, Price L, Pereira BJ, Jaber BL. Epid emiology and outcomes of 
acute renal failure in hospitalized subject s: a national survey.  Clin J Am Soc 
Nephrol.   2006;1:43 -51. 
 
Silver, S, Chertow, G. The Economic Consequences of Acute Kidney Injury. Nephron Clinical 
Practice. 2017;137:297 -301. 
 
Susantitaphong P, Cruz D, Cerda J, et al.  World incidence of AKI: a meta -analysis.   Clin J 
Am Nephrol. 2013;8(9):1482 -93. 
 
Tögel F, Westenfelder C. Recent advances in the understanding of acute kidney 
injury.   F1000Prime Rep. 2014;6:83.  
 
Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG. Chronic dialysis and 
death among survivors of acute kidney injury requiring dialysis. JAMA. 2009;302:1179 -85. 
 
Xue JL, Daniels F, Star RA. Incidence and mortality of acute renal failure in Medicare 
beneficiar ies, 1992 to 2001. J Am Soc Nephrol. 2006;17:1135 -42. 
 
Zager RA, Baltes LA, Sharma HM, Jurkowitz MS.  Responses of the ischemic acute renal 
failure kidney to additional ischemic events.   Kidney Int.   1984;26:689 -700. 
 
Zager RA, Burkhart KM, Gmur DJ. Postischemic proximal tubular resistance to oxidant stress 
and Ca2+ ionophone- induced attack.   Implications for reperfusion injury. Lab 
Invest.   1995 a;72:592 -600. 
 
Zager RA.   Heme protein -induced tubular cytoresistance: expression at the plasma membrane 
level.   Kidney Int. 1995 b;47:628 -37. 
 
Zager RA. Obstruction of proximal tubules initiates cytoresistance against hypoxic 
damage.   Kidney Int. 1995 c;47:628 -37. 
 
Zager RA, Johnson AC, Frostad KB. Combined iron sucrose and protoporphyrin treatment 
protects against ischemic and toxin -mediated acute renal failure. Kidney Int. 2016;90:67 -76. 
   Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008
Protocol Number: REN -003 (Original)  
Date: 25 March  2019 
 CONFIDENTIAL  Page 38 of 38 
Appendix 1 Safety Clinical Chemistry , Hematology, and Urinalysis Tests Perfo rmed by 
the L aboratory at Screening, During the Study , and at Follow- up (EOS)  
Clinical Chemistry1 Hematology2 
Total protein  Hemoglobin  
Albumin  Hematocrit  
Bicarbonate  Erythrocyte count (red blood cells ) 
Blood urea nitrogen  (BUN) 5 Differential leukocytes  
Creatinine5 Total leukocytes ( white blood cells ) 
Total bilirubin  Platelets  
Alkaline phosphatase  Urinalysis3 
Glucose  pH 
Sodium  Specific gravity 
Potassium  Glucose 
Inorganic phosphate  Ketones  
Calcium (total and ionized)  Bilirubin  
Magnesium  Urobilinogen  
Gamma -glutamyl transferase  
Alanine aminotransferase (ALT)  
Aspartate aminotransferase (AST)  
Cystatin -C5 
Tin5 
Tin Protoporphyrin IL-6 
Total porphyrins  Blood  
P21 
HO-1 Hemopexin 
Ferritin  
Urine sediment  
Urine samples to test for SnPP response  SnPP Urinary excretion
3’ 
N acetyl -beta-D-glucosaminidase (NAG)  
Kidney Injury Molecule -1 (KIM -1) 
Neutrophil Gelatinase -Associated Lipocalin 
(NGAL)  
Cystatin -C 
Albuminuria  
Urine pregnancy test4 
 
 
Response  Biomarkers   
Haptoglobin  
Ferritin  
Hemopexin  
IL-10 
P21 
HO-1 
Bilirubin5   
 
1 Collect into serum separator tubes . 
2 Collect into K2 EDTA tubes .  
3 Approximately 10 mL of urine required for urinalysis including sediment.  
3’ Urinary excretion to be tested in a 24 -hour volume sample 
4 Urine dipstick: all women of childbearing potential prior to the first dose of SnPP  on Study Day 1 and End of Study . Perform in 
the clinic using the pregnancy kit supplied by the laboratory . 
5       Biomarkers run with standard Chemistry samples   Renibus Therapeutics, Inc., RBT-1 IND 138109, SN 0008